• Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!

  • Mar 28 2025
  • Duración: 23 m
  • Podcast

Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, Selina Luger, MD, FRCPC, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, Harry Erba, MD, PhD, Duke University, Durham, NC, Fabio Guolo, MD, University of Genoa, Genoa, Italy, and David Sallman, MD, Moffitt Cancer Center, Tampa, FL.

    The experts discuss key trials in this space, including venetoclax combined with intensive induction chemotherapy, a Phase II study comparing midostaurin with gilteritinib in FLT3-mutated AML (NCT03836209), and the combination of ziftomenib with intensive chemotherapy. They also examine the role of CPX-351 in induction therapy and its potential combination with gemtuzumab ozogamicin.
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles